ImmunoGen, Inc.
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
26
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for Therapeutic Combinations Comprising ANTI-CD123 Immunoconjugates (US 11,701,428) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 3 fees due Feb 6 to 22, 2027 · next Feb 6
- 3 fees due Mar 5 to 19, 2027 · next Mar 5
- 7 fees due Apr 8 to 29, 2027 · next Apr 8
- 1 fee due May 3, 2027The maintenance fee for CD20 antibodies and uses thereof (US 9,175,086) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 5 fees due Jun 1 to 5, 2027 · next Jun 1
- 2 fees due Jul 26 to 28, 2027 · next Jul 26
- 2 fees due Aug 13 to 23, 2027 · next Aug 13
- 1 fee due Sep 19, 2027The maintenance fee for Method for Increasing the Efficacy of Cancer Therapy by Administering an ANTI-FOLR1 Immunoconjugate (US 11,932,701) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
- 2 fees due Oct 2 to 7, 2027 · next Oct 2
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,471,536 | Process for preparing purified drug conjugates In force · From the USPTO record | In force | From the USPTO record | |
| US 8,499,893 | Oil Scavenge System Having Churning Damper for Gas Turbine Engines In force · High confidence | In force | High confidence | |
| US 7,811,572 | Process for preparing purified drug conjugates In force · From the USPTO record | In force | From the USPTO record | |
| US 7,989,598 | Method of Targeting Specific Cell Populations Using Cell-Binding Agent Maytansinoid Conjugates Linked via a Non-Cleavable Linker, Said Conjugates and Methods of Making Said Conjugates In force · High confidence | In force | High confidence | |
| US 8,088,387 | Method of Targeting Specific Cell Populations Using Cell-Binding Agent Maytansinoid Conjugates Linked via a Non-Cleavable Linker, Said Conjugates, and Methods of Making Said Conjugates In force · High confidence | In force | High confidence | |
| US 8,119,813 | Method for Preparing Enantiomerically Enriched N-Carboxyanhydride In force · High confidence | In force | High confidence | |
| US 8,613,930 | Cross-Linkers and Their Uses In force · High confidence | In force | High confidence | |
| US 9,061,995 | Cross-Linkers and Their Uses In force · Low confidence | In force | Low confidence | |
| US 9,498,541 | Cross-Linkers and Their Uses In force · Medium confidence | In force | Medium confidence | |
| US 10,494,431 | Cross-Linkers and Their Uses In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 119: 11 patents in force now held by others · 102 lapsed for an unpaid fee · 43 ended at full term · 1 past the fee grace period · 3 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
15 pending · 43 abandoned · 80 no status recorded